Everolimus

BreastfeedingPediatric
  • TRADE NAMES: Afinitor (Novartis); Certican (Novartis); Zortress (Novartis)
  • INDICATIONS: Prophylaxis of organ rejection in adults following kidney or liver transplant; advanced renal cell carcinoma; neuroendocrine tumors of pancreatic, gastrointestinal or lung origin; breast cancer in post-menopausal women with advanced hormone-receptor positive, HER2-negative type cancer; renal angiomyolipoma and tuberous sclerosis complex; subependymal giant cell astrocytoma associated with tuberous sclerosis
  • CLASS: Antineoplastic, Immunosuppressant, mTOR inhibitor
  • HALF-LIFE: ~30 hours

In immunosuppression therapy: MALIGNANCIES AND SERIOUS INFECTIONS, KIDNEY GRAFT THROMBOSIS; NEPHROTOXICITY

In heart transplantation: MORTALITY


See full prescribing information for complete boxed warning.

Our database has 178 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
HAIR.
NAILS.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
OTIC.
RENAL.
RESPIRATORY.
OTHER.


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of everolimus in kidney transplantation in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 06/25/2020

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top